tive in primary tumor and PR-negative in metastatic tissues.  There were significant differences in OS (log-rank, *P* \< 0.000, Figure [0A](#F0){ref-type="fig"}) and post-recurrent survival (log-rank, *P* \< 0.000, Figure [0B](#F0){ref-type="fig"}) among the 0 groups. The median OS was 000 (00% CI 00-NA) months in Group A, 00